Boehringer Ingelheim· @Boehringer · X·· 2026-01-27AI 评分40
AI 导读
#NEWS：我们已与先声药业集团达成合作，推进一款用于炎症性肠病的新型双特异性抗体。两条已验证通路，一个分子，旨在提供更简单、更好的治疗选择。 了解更多：https://go.boehringer.com/VUcXm #IBD #CrohnsDisease
正文
#NEWS: We’ve partnered with Simcere Pharmaceutical Group to advance a novel bispecific antibody for inflammatory bowel disease. Two proven pathways, one molecule, aiming for simpler, better treatment options.
Learn more: https://go.boehringer.com/VUcXm
#IBD #CrohnsDisease
来源：Boehringer Ingelheim · x.com